BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Mar 25, 2025 • 14min
Oxford, UK based Greywolf Therapeutics is pursuing cancer and autoimmune indications by attempting to target T-cells at their first signal of activation - an approach the company leads the field on
Co-Founder and CEO Peter Joyce describes the science behind this, including how the company's lead programs inhibit Endoplasmic Reticulum Associated Proteases (ERAPs). A clinical stage company, he describes Greywolf's clinical experience and fundraising history.
Mar 20, 2025 • 13min
Brainomix, an Oxford, UK based company that uses AI to help front line physicians analyze CT scans for stroke damage and interstitial lung disease, announced an $18M series C raise today
Co-Founder and CEO Michalis Papadakis describes the unmet need for a quick, accurate assessment of stroke damage by front line physicians, who otherwise might not be experts in the area. Plus, moving the technology to lung disease and beyond.
Mar 19, 2025 • 10min
AnaptysBio's CEO discusses recent 12 week RA data from the company's PD-1 depleter and agonist, rosnilimab, and previews other upcoming catalysts
Daniel Faga goes over the recently released rosnilimab RA data and previews a longer-term follow-up that will be out in the second quarter. Plus, ulcerative colitis data that will be out in the fourth quarter and the opportunity there. He also highlights the company's PD-1 for oncology that is commercialized by GSK.
Mar 18, 2025 • 24min
Analyst Tuesdays: Mizuho Senior Analyst Graig Suvannavejh shares his take on the difficult biotech environment and discusses upcoming clinical trail catalysts for companies he covers
He sets the table for upcoming readouts from Axsome, Vigil Neuro, Verastem, Corvus, and Harmony Biosciences.
Mar 17, 2025 • 17min
The co-founders of Vevo Therapeutics describe the Arc Virtual Cell Atlas, a large single cell atlas made publicly available with Arc Institute that now includes Vevo's Tahoe-100M database
CEO Nima Alidoust and CSO Johnny Yu describe Vevo's contribution of 100M cells, plus a 60,000 drug-patient interaction map, that has been combined with Arc's 200M cell gene expression data from 21 different species (scBaseCamp). They explain the size and scale of this now open source atlas, and the potential utility of it to outside researchers.
Mar 14, 2025 • 11min
From struggling with sickle cell disease to climbing mountains - a firsthand account of how gene therapy has been life changing
Jimi Olaghere describes how his life has changed after participating in a clinical trial for the CRISPR based gene therapy for sickle cell disease that is now called CASGEVY. He describes what it was like receiving the treatment, and discusses the need for more awareness and access in the sickle cell community worldwide for this type of treatment.
Mar 14, 2025 • 19min
Bonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its target
Founder & CEO John Mulligan describes how he and his team sold an asset using the same science to Roche in 2022 for $250 million when they were Good Therapeutics, and how the follow-on company Bonum aims to test this approach more broadly. He describes how it works, and discusses the initial programs they have chosen, with a LAG3-IL2 being the most advanced.
Mar 14, 2025 • 6min
Alta Partners' Managing Director Bob More shares his take on biotech and his philosophy of investing in people - from the Timmerman Report 10th Anniversary Celebration in Seattle
He discusses the current downturn, they key of being focused, and his preference of investing in people first. Plus, comments on portfolio companies eGenesis and Vir Biotechnology.
Mar 14, 2025 • 6min
Congratulations to Luke Timmerman on 10 years of Timmerman Report. We salute you!
Celebrating with the Seattle (and beyond) biotech community.
Mar 13, 2025 • 7min
Tour of Scotland: Glasgow based EnteroBiotix is developing microbiome based treatments using a 'full ecosystem' of strains you would expect to see in a healthy microbiome
CEO Jame Mcllroy describes the scientific platform and how it contrasts to other microbiome approaches. A trial in IBS is scheduled to read out immanently.
